Keyphrases
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
100%
Non-relapse Mortality
100%
Follistatin
100%
Soluble Endoglin
100%
Hematopoietic Stem Cell Transplantation
57%
Angiogenic Factors
57%
Graft-versus-host Disease (GvHD)
42%
Treatment Toxicity
28%
Patient-specific
14%
Clinical Trials Network
14%
Vascular Endothelial Growth Factor Receptor (VEGFR)
14%
Plasma Samples
14%
Multivariate Analysis
14%
Endothelial Damage
14%
Confidence Interval
14%
Additive Effect
14%
Myeloablative
14%
Placental Growth Factor (PlGF)
14%
Hazard Ratio
14%
Non-associated
14%
Circulating Levels
14%
Epidermal Growth Factor
14%
Factor Level
14%
Vascular Endothelial Growth Factor
14%
Marrow Transplantation
14%
Tissue Injury
14%
Graft-versus-host Disease Prophylaxis
14%
Angiopoietin-2
14%
Specific Vulnerability
14%
Vascular Endothelial Growth Factor B
14%
Biochemistry, Genetics and Molecular Biology
Cell Transplantation
100%
Endoglin
100%
Follistatin
100%
Hematopoietic Cell
100%
Hematopoietic Stem Cell Transplantation
57%
Clinical Trial
14%
Multivariate Analysis
14%
Angiopoietin-2
14%
Epidermal Growth Factor
14%
Placental Growth Factor
14%
Vascular Endothelial Growth Factor A
14%
VEGF Receptors
14%
Blood Plasma
14%
Immunology and Microbiology
Cell Transplantation
100%
Hematopoietic Cell
100%
Endoglin
100%
Angiogenic Factor
57%
Hematopoietic Stem Cell Transplantation
57%
Acute Graft Versus Host Disease
42%
Graft-Versus-Host Disease
14%
Blood Plasma
14%
Vasculotropin
14%
Vasculotropin A
14%
Angiopoietin 2
14%
Epidermal Growth Factor
14%
Placental Growth Factor
14%
Neuroscience
Endoglin
100%
Follistatin
100%
Hematopoietic Cell
100%
Angiogenic Factor
57%
Epidermal Growth Factor
14%
Vasculotropin Receptor 1
14%
Vasculotropin A
14%
Placental Growth Factor
14%
Angiopoietin 2
14%
Blood Plasma
14%